Comparison between Eris Lifesciences IPO and SIS IPO.
Eris Lifesciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while SIS IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Eris Lifesciences IPO is up to ₹1,740.49 Cr whereas the issue size of the SIS IPO is up to ₹779.58 Cr. The final issue price of Eris Lifesciences IPO is ₹603.00 per share and of SIS IPO is ₹815.00 per share.
| Eris Lifesciences IPO | SIS IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹10 per share |
| Issue Price (Lower) | ₹600.00 per share | ₹805.00 per share |
| Issue Price (Upper) | ₹603.00 per share | ₹815.00 per share |
| Issue Price (Final) | ₹603.00 per share | ₹815.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹60.00 per share | |
| Market Lot Size | 24 shares | 18 shares |
| Fresh Issue Size | 0 shares | 44,44,785 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹362.25 Cr |
| OFS Issue Size | 2,88,75,000 shares | 51,20,619 shares |
| OFS Issue Size (Amount) | up to ₹1,740.49 Cr | up to ₹417.33 Cr |
| Issue Size Total | 2,88,75,000 shares | 95,65,404 shares |
| Issue Size Total (Amount) | up to ₹1,740.49 Cr | up to ₹779.58 Cr |
Eris Lifesciences IPO opens on Jun 16, 2017, while SIS IPO opens on Jul 31, 2017. The closing date of Eris Lifesciences IPO and SIS IPO is Jun 20, 2017, and Aug 02, 2017, respectively.
| Eris Lifesciences IPO | SIS IPO | |
|---|---|---|
| Anchor Bid Date | Jun 15, 2017 | Jul 28, 2017 |
| Issue Open | Jun 16, 2017 | Jul 31, 2017 |
| Issue Close | Jun 20, 2017 | Aug 02, 2017 |
| Basis Of Allotment (Tentative) | Jun 23, 2017 | Aug 07, 2017 |
| Initiation of Refunds (Tentative) | Jun 27, 2017 | Aug 08, 2017 |
| Credit of Share (Tentative) | Jun 28, 2017 | Aug 09, 2017 |
| Listing date (Tentative) | Jun 29, 2017 | Aug 10, 2017 |
| Anchor Lockin End date 1 | Jul 23, 2017 | Sep 06, 2017 |
| Anchor Lockin End date 2 | Sep 21, 2017 | Nov 05, 2017 |
Eris Lifesciences IPO P/E ratio is , as compared to SIS IPO P/E ratio of .
| Eris Lifesciences IPO | SIS IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | ||||||
| Promoter Shareholding (Post-Issue) | ||||||
| P/E Ratio | ||||||
| Market Cap | ₹8291.25 Cr. | ₹5962.46 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Eris Lifesciences IPO Retail Individual Investors (RII) are offered 28,72,500 shares while in SIS IPO retail investors are offered 28,72,500 shares. Qualified Institutional Buyers (QIB) are offered 86,17,500 shares in Eris Lifesciences IPO and 28,69,622 shares in SIS IPO.
| Eris Lifesciences IPO | SIS IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,29,26,250 shares | 43,04,432 shares |
| Market Maker Reservation | ||
| QIB | 86,17,500 shares | 28,69,622 shares |
| NII | 43,08,750 shares | 14,34,810 shares |
| RII | 28,72,500 shares | 9,56,540 shares |
| Employee | 1,50,000 shares | |
| Others | ||
| Total | 2,88,75,000 shares | 95,65,404 shares |
Eris Lifesciences IPO subscribed 3.29x in total, whereas SIS IPO subscribed 7.07x.
| Eris Lifesciences IPO | SIS IPO | |
|---|---|---|
| QIB (times) | 4.68x | 5.64x |
| NII (times) | 0.45x | 1.66x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.51x | 19.51x |
| Employee (times) | 0.86x | |
| Other (times) | ||
| Total (times) | 3.29x | 7.07x |
